Retaining U.S. marketing rights for itself, Acusphere Inc. signed a deal with Nycomed Group for the European rights to its lead product, AI-700. (BioWorld Today)

If there is a textbook formula for when to conduct a public offering, Pharmion Corp. might have followed it to the letter on Thursday, raising $220.8 million just six weeks after receiving FDA approval for Vidaza. (BioWorld Today)

Amgen Inc.'s therapy for Parkinson's disease failed to meet its primary endpoint in a Phase II study. (BioWorld Today)

About seven years since its inception, Vectura Ltd. dipped its feet into public waters on Friday, conducting an initial public offering on London's Alternative Investment Market to raise £20 million (US$36.4 million). (BioWorld Today)

Just as researchers geared up to start a second pivotal trial of iseganan in ventilator-associated pneumonia (VAP), the floor fell from beneath IntraBiotics Pharmaceuticals Inc. Wednesday. (BioWorld Today)

In a deal potentially worth $384 million for Vertex Pharmaceuticals Inc., the company entered a global collaboration with Merck & Co. Inc. to develop and commercialize the former's lead aurora kinase inhibitor, VX-680. (BioWorld Today)